About abeona therapeutics - ABEO
Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life-threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA), and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in Cleveland, OH.
ABEO At a Glance
Abeona Therapeutics, Inc.
6555 Carnegie Avenue
Cleveland, Ohio 44103
| Phone | 1-646-813-4701 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -63,734,000.00 | |
| Sector | Health Technology | Employees | 136 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
ABEO Valuation
| P/E Current | 4.445 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 5.774 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -2.506 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.15 |
ABEO Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -468,632.353 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
ABEO Liquidity
| Current Ratio | 6.08 |
| Quick Ratio | 6.08 |
| Cash Ratio | 5.912 |
ABEO Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -73.709 |
| Return on Equity | -216.572 |
| Return on Total Capital | -95.013 |
| Return on Invested Capital | -160.22 |
ABEO Capital Structure
| Total Debt to Total Equity | 52.345 |
| Total Debt to Total Capital | 34.359 |
| Total Debt to Total Assets | 21.158 |
| Long-Term Debt to Equity | 37.017 |
| Long-Term Debt to Total Capital | 24.298 |